Novartis Executes Sandoz Spin-off, Completing Strategic Transformation into a Leading, Focused Innovative Medicines Company

3:04:25 PM | 4/1/2024

On April 1, Novartis Vietnam Ltd. (“Novartis Vietnam”), an affiliate of Novartis, a global healthcare company, today announced the Spin-off of Sandoz - its Generics & Biosimilar business. With effect from April 1st, 2024, Sandoz will no longer be part of Novartis business in Vietnam.

In alignment with its new global strategy unveiled in 2022, Novartis Vietnam has now transformed into a focused innovative medicines business, concentrated on four core therapeutic areas: Cardiovascular and renal metabolic, Oncology, Immunology, and Neuroscience. Multiple significant in-market and pipeline assets in each of these areas offer the opportunity for Novartis Vietnam to address high disease burden with unmet needs.

Mrs. Karina Ng, Country President, Novartis Vietnam

Said Mrs. Karina Ng, Country President, Novartis Vietnam: “This is a truly historic moment for Novartis and Sandoz, as we begin new chapters as independent companies. From now on, Novartis will emerge as a fully focused innovative medicines company. As we enter this new era with a strong pipeline, we remain consistent in our commitment to expanding access to innovative treatments to patients in Vietnam by building strategic partnerships with key stakeholders including the government, medical societies, patient communities, private sector, academies, and civil organizations. By leveraging collective strengths, we aim to achieve the shared goal of strengthening Vietnam’s healthcare system, saving and improving lives for people, and contributing to the socioeconomic development of the country.”

Novartis has been operating representative offices in Vietnam since 2008. In February 2019, Novartis Vietnam Ltd. became one of the first multinational pharmaceutical companies to successfully transform into a foreign-invested enterprise and fully operationalize its import activities. Over the years, Novartis has made substantial contributions to support the Vietnam economy and improve health outcomes of patients in the country. In 2022, the full Novartis portfolio of medicines reached 5.6 million Vietnamese patients across 49 Novartis innovative medicine brands.

Novartis is one of the leaders in R&D investment in Vietnam. Since 2011, Novartis invested a total of 25 million US dollars in 62 clinical trials in a broad range of therapeutic areas. Over one thousand investigators and site staff were trained and gained experience in clinical trials conducted in over 130 sites across 30 hospitals.

Novartis aims to be the trusted partner of the healthcare system in Vietnam. Thanks to its efforts in strengthening Vietnam’s healthcare system and contributing to the socioeconomic development of the country, the company has been awarded three Certificates of Merit by the Ministry of Health for contributions in saving and improving people’s lives (in 2016), contributions to the digital transformation of the health sector in Vietnam (in 2020) and commitment to social responsibility during the COVID-19 pandemic (in 2021). In 2023, the Ministry of Labor, Invalids and Social Affairs also recognized Novartis for its significant contributions to children’s health in 2023, particularly through the project aimed at raising awareness and bolstering support for children with Spinal Muscular Atrophy (SMA) in Vietnam.

With two offices in Ho Chi Minh and Hanoi, Novartis currently employs over 250 Vietnamese employees. Novartis has been constantly ranked among the Top 100 Best Places to Work in Vietnam since 2014. In 2022, Novartis was honored one of the Best Places to Work for in Asia by HR Asia.

H.N (Vietnam Business Forum)